Tumor selective uptake of drug-nanodiamond complexes improves therapeutic outcome in pancreatic cancer.

Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related deaths and novel treatment approaches are urgently needed. Here we show that poly(ethylene glycol)-functionalized nanodiamonds loaded with doxorubicin (ND-PEG-DOX) afforded a considerable improvement over free drug in an orthotopic pancreatic xenograft model. ND-PEG-DOX complexes were also superior to free DOX in 3-dimensional (3D) tumor spheroids of PDAC. ND-PEG showed no cytotoxicity towards macrophages, and histopathological analysis showed no abnormalities of major organs upon in vivo administration of ND-PEG-DOX. These results provide evidence that ND-mediated drug delivery may serve as a means of improving the therapeutic outcome in PDAC.

[1]  B. Fadeel,et al.  Macrophage activation status determines the internalization of mesoporous silica particles of different sizes: Exploring the role of different pattern recognition receptors. , 2017, Biomaterials.

[2]  A. Goga,et al.  Nanodiamond Therapeutic Delivery Agents Mediate Enhanced Chemoresistant Tumor Treatment , 2011, Science Translational Medicine.

[3]  P. Kantoff,et al.  Cancer nanomedicine: progress, challenges and opportunities , 2016, Nature Reviews Cancer.

[4]  Xin Wang,et al.  Epirubicin-Adsorbed Nanodiamonds Kill Chemoresistant Hepatic Cancer Stem Cells , 2014, ACS nano.

[5]  Yury Gogotsi,et al.  The properties and applications of nanodiamonds. , 2011, Nature nanotechnology.

[6]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[7]  Bengt Fadeel,et al.  Safety assessment of nanomaterials: implications for nanomedicine. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[8]  Jing Bai,et al.  Salt-induced aggregation of gold nanoparticles for photoacoustic imaging and photothermal therapy of cancer. , 2016, Nanoscale.

[9]  R. Jain,et al.  Engineering and physical sciences in oncology: challenges and opportunities , 2017, Nature Reviews Cancer.

[10]  P. Hwang,et al.  Nanodiamonds enhance therapeutic efficacy of doxorubicin in treating metastatic hormone-refractory prostate cancer , 2014, Nanotechnology.

[11]  Rachael M. Crist,et al.  Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer , 2016, Nature Reviews Clinical Oncology.

[12]  Dean Ho,et al.  Nanodiamonds: The intersection of nanotechnology, drug development, and personalized medicine , 2015, Science Advances.

[13]  D. Ho,et al.  Biocompatibility Assessment of Detonation Nanodiamond in Non-Human Primates and Rats Using Histological, Hematologic, and Urine Analysis. , 2016, ACS nano.

[14]  Yuanwei Chen,et al.  Biodistribution and fate of nanodiamonds in vivo , 2009 .

[15]  Jiye Shi,et al.  One‐Shot Immunomodulatory Nanodiamond Agents for Cancer Immunotherapy , 2016, Advanced materials.

[16]  D. Leong,et al.  Probing the relevance of 3D cancer models in nanomedicine research. , 2014, Advanced drug delivery reviews.

[17]  David W Grainger,et al.  Nanoparticles in medicine: Current challenges facing inorganic nanoparticle toxicity assessments and standardizations. , 2015, Nanomedicine : nanotechnology, biology, and medicine.

[18]  Rebecca L. Siegel Mph,et al.  Cancer statistics, 2018 , 2018 .

[19]  Sanjay Mathur,et al.  Targeted uptake of folic acid-functionalized iron oxide nanoparticles by ovarian cancer cells in the presence but not in the absence of serum. , 2014, Nanomedicine : nanotechnology, biology, and medicine.

[20]  Sang Kyu Kwak,et al.  Cloaking nanoparticles with protein corona shield for targeted drug delivery , 2018, Nature Communications.

[21]  Huan-Cheng Chang,et al.  The long-term stability and biocompatibility of fluorescent nanodiamond as an in vivo contrast agent. , 2012, Biomaterials.

[22]  Bengt Fadeel,et al.  Mechanisms of carbon nanotube-induced toxicity: focus on pulmonary inflammation. , 2013, Advanced drug delivery reviews.

[23]  F. Cheng,et al.  Smart pH-responsive and high doxorubicin loading nanodiamond for in vivo selective targeting, imaging, and enhancement of anticancer therapy. , 2016, Journal of materials chemistry. B.

[24]  P. Ross,et al.  FOLFIRINOX – a new paradigm in the treatment of pancreatic cancer , 2014, Expert review of anticancer therapy.

[25]  N. Jamieson,et al.  nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial , 2015 .

[26]  Chitta Ranjan Patra,et al.  Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. , 2010, Advanced drug delivery reviews.

[27]  A. Nel,et al.  Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care. , 2017, ACS nano.

[28]  M. Gottesman,et al.  Revisiting the role of ABC transporters in multidrug-resistant cancer , 2018, Nature Reviews Cancer.

[29]  D. Mukhopadhyay,et al.  Genetic status of KRAS modulates the role of Neuropilin-1 in tumorigenesis , 2017, Scientific Reports.

[30]  Bengt Fadeel,et al.  Biological interactions of carbon-based nanomaterials: From coronation to degradation. , 2016, Nanomedicine : nanotechnology, biology, and medicine.

[31]  V. Chung,et al.  Targeted Therapies for Pancreatic Cancer , 2018, Cancers.

[32]  Tiancheng Wang,et al.  Pulmonary toxicity and translocation of nanodiamonds in mice , 2010 .

[33]  Dan Peer,et al.  Progress and challenges towards targeted delivery of cancer therapeutics , 2018, Nature Communications.

[34]  Shinji Tanaka.  Molecular Pathogenesis and Targeted Therapy of Pancreatic Cancer , 2016, Annals of surgical oncology.

[35]  Kun Chen,et al.  Aggregation behavior of nanodiamonds and their functionalized analogs in an aqueous environment. , 2014, Environmental science. Processes & impacts.

[36]  Ling Ye,et al.  TAT-conjugated nanodiamond for the enhanced delivery of doxorubicin , 2011 .

[37]  R. Jesenofsky,et al.  Desmoplasia and Chemoresistance in Pancreatic Cancer , 2014, Cancers.

[38]  U. Holzwarth,et al.  Mapping of the available standards against the regulatory needs for nanomedicines , 2018, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[39]  Xianjun Yu,et al.  Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going , 2017, Experimental & Molecular Medicine.

[40]  M. I. Setyawati,et al.  Tuning Endothelial Permeability with Functionalized Nanodiamonds. , 2016, ACS nano.